Studie kopplar GLP-1-läkemedel till lägre risk för bröstcancer

6 juni 2026

Rapporterad av AI

Kvinnor som tar GLP-1-läkemedel som Ozempic och Wegovy uppvisade cirka 30 procent lägre sannolikhet att utveckla bröstcancer i en omfattande observationsstudie.

Forskare granskade elektroniska patientjournaler från mer än 111 000 kvinnor i åldrarna 45 till 80 med ett kroppsmasseindex på 25 eller högre, vilka genomgick bröströntgen vid Penn Medicine mellan januari 2022 och juni 2025. De som ordinerats GLP-1-läkemedel hade 35,1 procent lägre sannolikhet för bröstcancer i hela gruppen och 30,5 procent lägre sannolikhet i en matchad analys. Resultaten presenterades vid 2026 års årsmöte för American Society of Clinical Oncology och publicerades i JCO Oncology Practice. Elizabeth McDonald, professor vid University of Pennsylvania Perelman School of Medicine, påpekade att studien var observationell och inte bevisar ett orsakssamband. McDonald och hennes kollegor planerar att inleda kliniska prövningar för att testa om GLP-1-läkemedel kan bidra till att förebygga bröstcancer hos högriskgrupper. Läkemedlen påverkar signalvägar som är kopplade till cancerutveckling, även om viktminskning också kan bidra till den observerade fördelen.

Relaterade artiklar

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

5 maj 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

21 maj 2026 Rapporterad av AI Faktagranskad

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Hälsa

Semaglutide shows strong weight loss results for adults over 65

Hälsa

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

Teknik

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Teddi Mellencamp sought weight-loss meds amid stage 4 cancer battle

Teddi Mellencamp, the Real Housewives of Beverly Hills alum, spilled on her podcast that she begged her doctor for GLP-1 weight-loss drugs while battling cancer. She gained weight from steroids but got shut down. Joking about the irony, she quipped about living her best life without the meds.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

1 april 2026 Rapporterad av AI

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Researchers at Vanderbilt Health discovered that both popular weight loss drugs and bariatric surgery significantly reduce fat mass while causing modest losses in fat-free mass, including muscle, in patients with obesity. The findings, based on over 3,000 patients, show improvements in overall body composition over 24 months. Maintaining this balance is crucial for long-term health, the study emphasizes.

5 juni 2026 14:44

Studie kopplar GLP-1-läkemedel till lägre risk för bröstcancer

Relaterade artiklar

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Study links Ozempic to lower depression and anxiety risks

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Semaglutide shows strong weight loss results for adults over 65

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Teddi Mellencamp sought weight-loss meds amid stage 4 cancer battle

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

Study finds olive oil fat speeds pancreatic cancer in mice

Analysis of FDA reports finds stronger safety signal for rare optic nerve injury with Wegovy than with Ozempic

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Trojan horse obesity drug boosts weight loss in mice

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Gut reset procedure limits weight regain after stopping Ozempic

Researchers map hindbrain circuit through which hormone FGF21 drives weight loss in obese mice

GLP-1 weight loss drugs boost premium chocolate sales

Denna webbplats använder cookies